Transition metals and polyol pathway in the development of diabetic neuropathy in rats

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue 5, 2002, Pages 395-402

  Nakamura, Jiro ^a   Hamada, Yoji ^a   Chaya, Sadao ^a   Nakashima, Eitaro ^a   Naruse, Keiko ^a   Kato, Koichi ^a   Yasuda, Yutaka ^a   Kamiya, Hideki ^a   Sakakibara, Fumihiko ^a   Koh, Naoki ^a   Hotta, Nigishi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aldose reductase inhibitor; Autoxidation; Diabetic neuropathy; Metal chelator; Oxidative stress; Polyol pathway

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; CHELATING AGENT; MALONALDEHYDE; OXYGEN RADICAL; POLYOL; TRANSITION ELEMENT; TRIENTINE;

ARTICLE; BLOOD FLOW; CATALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETIC NEUROPATHY; ELECTROCARDIOGRAM; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCIATIC NERVE; THROMBOCYTE AGGREGATION;

ALDEHYDE REDUCTASE; ANIMALS; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; CHELATING AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; ELECTROCARDIOGRAPHY; MALE; MALONDIALDEHYDE; METALS; NEURAL CONDUCTION; PLATELET AGGREGATION; POLYMERS; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; SCIATIC NERVE; THIAZOLES; TRIETHYLENETETRAMINE;

EID: 0036711027     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.319     Document Type: Article

References (55)

1. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Int Med 1995; 122: 561-568.
2. The DCCT Research Group. Effect of intensive diabetes treatment on nerve conduction in the diabetes control and complications trial. Ann Neurol 1995; 38: 869-880.
3. Greene DA, Sima AAF, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992; 15: 1902-1925.
4. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46(Suppl. 2): S31-S37.
5. Stevens MJ, Feldman EF, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabetic Med 1995; 12: 566-579.
6. Dyck JP. Hypoxic neuropathy: Does hypoxia play a role in diabetic neuropathy? The 1988 Roberst Wartenberg lecture. Neurology 1989; 39: 111-118.
7. Cameron NE, Cotter MA. Comparison of the effects of ascorbyl-gamma-linolenic acid and gamma-linolenic acid in the correction of neurovascular deficits in diabetic rats. Diabetologia 1996; 39: 1047-1054.
8. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994; 37: 449-459.
9. Cameron NE, Cotter MA, Maxfield EK. Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 1993; 36: 299-304.
10. Karasu C, Dewhurst M, Stevens MJ, Tomlinson DR. Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids. Diabetologia 1995; 38: 129-134.
11. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-1167.
12. Nickander KK, McPhee BR, Low PA, Tritschler H. Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Rad Biol Med 1996; 21: 631-639.
13. Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA. Effects of DL-a-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress, in experimental diabetic neuropathy. Diabetes 2000; 49: 1006-1015.
14. Van Dam PS, Van Asbeck BS, Erkelens DW, Marx JJ, Gispen WH, Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev 1995; 11: 181-192.
15. Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past, present and future. Diabetes Care 1995; 44: 1355-1350.
16. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999; 53: 580-591.
17. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy. Diabetes Care 2001; 24: 1776-1782.
18. Tesfamariam B. Free radicals in diabetes endothelial cell dysfunction. Free Rad Biol Med 1994; 16: 383-391.
19. Jiang Z-Y, Woollard ACS, Wolff SP. Hydrogen peroxide production during experimental protein glycation. FEBS Lett 1990; 268: 69-71.
20. Wolff SP. Transition metals and oxidative stress in the complications of diabetes. In The Role of Anti-Oxidants in Diabetes Mellitus, Gries FA, Wessels K (eds). Pmi Verlagsgruppe: Frankfurt am Main, 1993; 82-101.
21. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 1989; 38: 1207-1210.
22. Qian M, Eaton JW. Glycochelates and the etiology of diabetic peripheral neuropathy. Free Radic Biol Med 2000; 28: 652-656.
23. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats: potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 1995; 96: 1159-1163.
24. Ishii A, Kotani T, Nagaki Y, et al. Highly selective aldose reductase inhibitors. 1,3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids. J Med Chem 1996; 39: 1924-1927.
25. Miyoshi T, Goto I. Serial in vivo determinations of nerve conduction velocity in rat tails: physiological and pathological changes. Electroencephalogr Clin Neurophysiol 1973; 35: 125-131.
26. Hotta N, Koh N, Sakakibara F, et al. Effects of beraprost sodium and insulin on the electroretinogram, nerve conduction, and nerve blood flow in rats with streptozotocin-induced diabetes. Diabetes 1996; 45: 361-366.
27. Nakamura J, Koh N, Sakakibara F, et al. Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats. Eur J Pharmacol 1995; 294: 207-214.
28. Nakamura J, Koh N, Sakakibara F, et al. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats. J Pharmacol Exp Ther 1998; 287: 897-902.
29. Hotta N, Nakamura J, Sakakibara F, et al. Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant. Am J Physiol 1997; 273: E965-E971.
30. Koshu K, Kamiyama K, Oka N, Endo S, Takaku A, Saito T. Measurement of regional blood flow using hydrogen gas generated by electrolysis. Stroke 1982; 13: 483-487.
31. Ardlie NG, Packham MA, Mustard JF. Adenosine diphosphate-induced platelet aggregation in suspension of washed rabbit platelets. Br J Haematol 1970; 19: 7-17.
32. Hara T, Nakamura J, Koh N, et al. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy. J Lab Clin Med 1995; 126: 541-547.
33. Mizuno K, Kato N, Matsubara A, Nakano K, Kurono M. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2,5-dioxospino chroman-4,4-imidazolidine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism 1992; 41: 1081-1086.
34. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
35. Bravenboer B, Kapelle AC, Hamers FPT, Van Buren T, Erkelens DW, Gispen WH. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rats. Diabetologia 1992; 35: 813-817.
36. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid. Diabetologia 1995; 38: 1425-1433.
37. Baynes JW. Role of oxidative stress in the development of complications in diabetes. Diabetes 1991; 40: 405-412.
38. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem J 1988; 256: 251-255.
39. Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sima AA, Greene DA. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 1993; 36: 608-614.
40. Bravi MC, Pietrangeli P, Laurenti O, et al. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. Metabolism 1997; 46: 1194-1198.
41. De Mattia G, Laurenti O, Bravi C, Ghiselli A, Iuliano L, Balsano F. Effect of aldose reductase inhibition on glutathione redox status in erythrocytes of diabetic patients. Metabolism 1994; 43: 965-968.
42. Yan H, Harding JJ. Glycation-induced inactivation and loss of antigenicity of catalase and superoxide dismutase. Biochem J 1997; 328: 599-605.
43. Lal S, Randall WC, Taylor AH, et al. Fructose-3-phosphate production and polyol pathway metabolism in diabetic rat hearts. Metabolism 1997; 46: 1333-1338.
44. Obrosova IG, Van Huysen C, Fathallah L, Cao X, Greene DA, Stevens MJ. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002; 16: 123-125.
45. Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997; 40: 271-281.
46. Keegan A, Cotter MA, Caneron NE. Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats. Free Radic Biol Med 1999; 27: 536-543.
47. Cameron NE, Cotter MA. Effects of an extracellular metal chelator on neurovascular function in diabetic rats. Diabetologia 2001; 44: 621-628.
48. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-1937.
49. Archibald V, Cotter MA, Cameron NE. Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments. Naunyn-Schmeideberg's Arch Pharmacol 1996; 353: 584-591.
50. Pieper GM, Siebeneich W. Diabetes-induced endothelial dysfunction is prevented by long-term treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine. J Cardiovasc Pharmacol 1997; 30: 734-738.
51. Cameron NE, Cotter MA. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway. Diabetologia 1992; 35: 1011-1019.
52. Otter DJ, Chess-Williams R. The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats. Br J Pharmacol 1994; 113: 576-580.
53. Moncada S, Palmer RJM, Higgs EA. Biosynthesis of nitric oxide from L-arginine. Br J Pharmadol 1989; 38: 1709-1715.
54. Ernst E, Matrai A. Altered red and white blood cell rheology in type 2 diabetes. Diabetes 1986; 35: 1412-1415.
55. Robey C, Dasmahapatra A, Cohen MP, Auarez S. Sorbinil partially prevents decreased erythrocyte deformability in experimental diabetes mellitus. Diabetes 1987; 36: 1010-1013.